Cyclo Therapeutics, Inc. CYTH
Set alert
At close · Mar 26
52-week range unavailable
- YTD
- +22.14%
- 1 year
- -49.61%
- Open
- 0.7206
- Prev close
- 0.7206
- Mkt cap
- 17.32M
- Vol
- 186.81K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.7206
- High
- 0.7206
- Forward P/E
- -0.91
- Beta
- -0.38
- Short ratio
- 3.82
- Inst. own
- 13.17%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 0.6972
- 200-d avg
- 1.06
- 1y target
- 0.95
Key statistics
- Market cap
- 17.32M
- Enterprise value
- 19.51M
- Trailing P/E
- 0.00
- Forward P/E
- -0.91
- PEG ratio
- 0.00
- Price / sales
- 15.29
- Price / book
- 3.60
- EPS (TTM)
- -0.90
- Beta
- -0.38
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 1.13M
- Revenue growth
- 5.10%
- Free cash flow
- -10.79M
- Total cash
- 1.12M
- Total debt
- 3.00M
- Return on equity
- 0.00%
- Shares outstanding
- 28.61M
- Short % of float
- 0.46%
- 50-day average
- 0.6972
- 200-day average
- 1.06
Analyst view
Consensus: none
Next earnings
Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 14, 2024 | Sep 1, 2024 | -0.17 | -0.26 | -0.09 | -52.94% |
| Aug 14, 2024 | Jun 1, 2024 | -0.14 | -0.21 | -0.07 | -50.00% |
| May 15, 2024 | Mar 1, 2024 | -0.20 | -0.15 | +0.05 | +25.00% |
| Mar 18, 2024 | Dec 1, 2023 | 0.00 | -0.23 | — | — |
| Nov 14, 2023 | Sep 1, 2023 | 0.00 | -0.29 | — | — |
| Aug 15, 2023 | Jun 1, 2023 | 0.00 | -0.33 | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Aug 27, 2024 | Maxim Group | down | Buy | Hold |
| Aug 26, 2024 | Ascendiant Capital | main | Buy | Buy |
| Aug 23, 2024 | HC Wainwright & Co. | down | Buy | Neutral |
| Aug 16, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 31, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| May 1, 2024 | HC Wainwright & Co. | init | — | Buy |
About Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease. It also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is headquartered in Gainesville, Florida.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- United States
- Website
- cyclotherapeutics.com
News
- 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- 12 Health Care Stocks Moving In Monday's Pre-Market Session
- 12 Health Care Stocks Moving In Friday's Pre-Market Session
- 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Why Bed Bath & Beyond Shares Are Trading Lower By 23%; Here Are 20 Stocks Moving Premarket
- Stocks That Hit 52-Week Lows On Monday
- Why Universal Electronics Shares Are Trading Lower By 30%? Here Are Other Stocks Moving In Friday's Mid-Day Session
- Why Tupperware Brands Shares Dipped Around 42%; Here Are 89 Biggest Movers From Yesterday
- Stocks That Hit 52-Week Lows On Friday
- Stocks That Hit 52-Week Lows On Friday
Your note
Sign in to keep a note on CYTH — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CONKLING WILLIAM | Director | Stock Award(Grant) | Nov 14, 2024 | 50,230 |
| CROSS SHAWN M. | Director | Stock Award(Grant) | Nov 14, 2024 | 107,749 |
| FINE N SCOTT | Chief Executive Officer | Conversion of Exercise of derivative security | Oct 19, 2023 | 743,804 |
| OSTRONIC FRANCIS PATRICK | Director | Stock Award(Grant) | Jun 2, 2024 | 348,771 |
| SHANAHAN WILLIAM S | Director | Stock Award(Grant) | Nov 14, 2024 | 148,826 |
| SIEGER MARKUS | Director | Stock Award(Grant) | Nov 14, 2024 | 382,122 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| EPIQ Capital Group, LLC | 2.57% | 739,426 | 445.13K | Sep 29, 2024 |
| Vanguard Group Inc | 2.08% | 598,694 | 360.41K | Sep 29, 2024 |
| Founders Fund V Management, LLC | 1.67% | 480,708 | 289.39K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.53% | 152,332 | 91.70K | Sep 29, 2024 |
| Founders Fund VI Management, LLC | 0.38% | 110,023 | 66.23K | Sep 29, 2024 |
| Blackrock Inc. | 0.29% | 83,521 | 50.28K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.52% | 437,611 | 263.44K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.56% | 161,083 | 96.97K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.33% | 96,073 | 57.84K | Oct 30, 2024 |
| iShares Micro Cap ETF | 0.15% | 43,615 | 26.26K | Oct 30, 2024 |
| Fidelity Series Total Market Index Fund | 0.06% | 17,413 | 10.48K | Oct 30, 2024 |
| Fidelity NASDAQ Composite Index Fund | 0.05% | 13,730 | 8.27K | Oct 30, 2024 |